Drug pricing, commercialization, pharma industry news
13 stories
In the last 7 days, Pharma tracked 8 stories — 13% positive, 50% negative, 38% neutral sentiment, averaging 6.8/10 impact.
Stories appear on this page because our classification stage assigned them this category as their primary topic — each story receives exactly one category per niche, chosen from a fixed list, so a story that touches both a funding round and a product launch in the same week sorts into whichever category best matches its dominant subject, not both. This keeps each category page focused on one beat rather than a blend of unrelated developments, and applies the same source-verification standard used across every story on this site. Sentiment measures the directional read of each development for this category specifically, not the tone of the reporting, and impact weights how consequential a development is — regulatory, financial, or operational — rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth.
Source: Seeking Alpha · Seeking Alpha
At the India AI Impact Summit 2026, Minister Ashwini Vaishnaw highlighted a growing global consensus on mitigating AI risks while prioritizing healthcare as a core sector for AI deployment. This shift signals a move toward impact-driven, regulated AI applications that could transform drug discovery and diagnostics.
Source: moneycontrol.com · businesstoday.in
The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036.
Source: weeklyvoice.com · admin (in)
The global Phenylketonuria (PKU) market is projected to expand significantly through 2034, fueled by a robust pipeline of next-generation therapies and enhanced diagnostic screening. With the United States leading in diagnosed prevalence, major players like BioMarin, PTC Therapeutics, and Jnana are racing to address the metabolic limitations of current standard-of-care treatments.
Source: admin (in) · prnewswire.com
Bayer has reached a $7.25 billion settlement agreement to resolve long-standing litigation surrounding its Roundup herbicide. The deal includes a 21-year framework designed to provide legal and financial certainty for the company following years of costly courtroom battles.
Beta Bionics and NeoGenomics reported robust Q4 2025 results, highlighting significant commercial momentum in autonomous insulin delivery and oncology diagnostics. Both companies emphasized operational efficiency and market expansion as key drivers for the upcoming fiscal year.
Source: insidermonkey.com · insidermonkey.com
Researchers at St. Jude Children’s Research Hospital have developed M-PACT, an artificial intelligence tool that classifies pediatric brain tumors using liquid biopsy data. By analyzing DNA methylation patterns in cerebrospinal fluid, the tool offers a minimally invasive alternative to traditional surgical biopsies.
Source: EurekAlert! · technologynetworks.com
Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Source: Seeking Alpha · Seeking Alpha
Healius's H1 earnings call highlighted a strategic focus on operational efficiency and pathology volume recovery in a challenging macroeconomic environment. As the diagnostic giant navigates rising labor costs and inflationary pressures, its performance serves as a critical indicator for the broader Australian healthcare services sector.
A global surge in pre-market trading on February 18, 2026, has highlighted significant gains for specialized biotech and MedTech entities. Parx Materials and Coltene Holding led the sector's movement as investors pivoted toward antimicrobial innovation and dental technology amid broader market volatility.
Google DeepMind CEO Demis Hassabis predicts Artificial General Intelligence (AGI) could arrive within five to eight years, ushering in a 'golden era of science' for drug discovery. While the timeline suggests a radical acceleration of biological engineering, Hassabis issued urgent warnings regarding biosecurity risks as AI systems gain autonomous capabilities.
Source: freepressjournal.in · moneycontrol.com
Researchers at UC San Diego have developed an artificial intelligence model that accurately predicts the risk of colorectal cancer in ulcerative colitis patients with low-grade dysplasia. This digital pathology tool addresses a critical clinical gap by identifying which patients require aggressive intervention versus those who can safely remain under surveillance.
Source: UC San Diego Today · news-medical.net
US equities faced a volatile session as investors reassessed the 'dark side' of AI disruption, dragging the Nasdaq into its fifth consecutive week of losses. Within the healthcare sector, attention is fixed on Medtronic's earnings and Masimo's performance as the industry grapples with shifting valuations.
Source: Benzinga · Yahoo Finance
According to our own tracking database, this category has accumulated 413 pharma stories since coverage began. This page aggregates the latest pharma stories within our biotech coverage area. Every story is cross-referenced across multiple primary sources, scored for sentiment and operational impact, and timestamped so fresh developments surface first. We track drug pricing, commercialization, pharma industry news and surface the angles a domain expert would actually read.
Story selection follows our editorial methodology — impact scoring weights regulatory, financial, and operational developments distinctly. Sentiment is classified across five tiers via supervised classification trained on labeled industry corpora. See our glossary for term definitions and our trends index for longitudinal patterns across the biotech beat.
Stories only surface on this page once the classifier scores them at a minimum 35 percent relevance to the category. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a wrong stat, a broken source link, a miscategorized story? Report a data issue.
| Signal | What it tells you |
|---|---|
| Verified by N sources | Confidence the story isn't a single-source rumor — N≥2 means the development is independently corroborated. |
| Impact score (1-10) | Estimated regulatory, financial, or operational impact. 8+ indicates a story experienced operators should act on. |
| Sentiment | Five-tier classification (very bullish through very bearish) trained on labeled biotech-specific corpora. |
| Time stamp | Recency. Fresh stories (under 1h) render with a highlighted timestamp; stale stories (≥24h) render dimmed. |